A Therapeutic OX40 Agonist Dynamically Alters Dendritic, Endothelial, and T Cell Subsets within the Established Tumor Microenvironment
- 14 November 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (22), 9041-9052
- https://doi.org/10.1158/0008-5472.can-10-1369
Abstract
Little preclinical modeling currently exists to support the use of OX40 agonists as therapeutic agents in the setting of advanced cancers, as well as the mechanisms through which therapeutic efficacy is achieved. We show that treatment of mice bearing well-established day 17 sarcomas with a novel OX40 ligand–Fc fusion protein (OX40L-Fc) resulted in tumor regression or dormancy in the majority of treated animals. Unexpectedly, dendritic cells (DC) in the progressive tumor microenvironment (TME) acquire OX40 expression and bind fluorescently labeled OX40L-Fc. Furthermore, longitudinal analyses revealed that DCs become enriched in the tumor-draining lymph node (TDLN) of both wild-type and Rag−/− mice within 3 days after OX40L-Fc treatment. By day 7 after treatment, a significant expansion of CXCR3+ T effector cells was noted in the TDLN, and by day 10 after treatment, type 1 polarized T cells exhibiting a reactivated memory phenotype had accumulated in the tumors. High levels of CXCL9 (a CXCR3 ligand) and enhanced expression of VCAM-1 by vascular endothelial cells (VEC) were observed in the TME early after treatment with OX40L-Fc. Notably, these vascular alterations were maintained in Rag−/− mice, indicating that the OX40L-Fc–mediated activation of both DC and VEC occurs in a T-cell–independent manner. Collectively, these findings support a paradigm in which the stimulation of DC, T cells, and the tumor vasculature by an OX40 agonist dynamically orchestrates the activation, expansion, and recruitment of therapeutic T cells into established tumors. Cancer Res; 70(22); 9041–52. ©2010 AACR.Keywords
Other Versions
This publication has 46 references indexed in Scilit:
- IL-4 Suppresses Very Late Antigen-4 Expression Which is Required for Therapeutic Th1 T-cell Trafficking Into TumorsJournal of Immunotherapy, 2009
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosisThe Journal of Experimental Medicine, 2009
- Integrating costimulatory agonists to optimize immune-based cancer therapiesImmunotherapy, 2009
- Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanomaThe Journal of Experimental Medicine, 2008
- Immune-mediated dormancy: an equilibrium with cancerJournal of Leukocyte Biology, 2008
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejectionThe Journal of Experimental Medicine, 2008
- Plasmacytoid dendritic cells induce NK cell–dependent, tumor antigen–specific T cell cross-priming and tumor regression in miceJCI Insight, 2008
- OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in miceJCI Insight, 2007
- Anti‐OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responsesEuropean Journal of Immunology, 2006
- CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsJCI Insight, 2006